Johnson & Johnson's (NYSE: JNJ) lumateperone (Caplyta) produced a statistically significant reduction in manic symptoms in bipolar I disorder in a pivotal Phase III trial, according to topline results released September 21 and presented at the 2026 Psych Congress Annual Meeting. Already approved for bipolar depression in both bipolar I and II disorder, J&J is now preparing to discuss an approval filing for mania with the FDA. If approved the molecule would one of the few agents covering both poles of the illness in a single oral formulation.
The randomized, double-blind, placebo-controlled Study 451 evaluated once-daily lumateperone 42 mg versus placebo over three weeks in adults with manic episodes, with or without mixed features, associated with bipolar I disorder. The drug produced a 4.8-point greater reduction in Young Mania Rating Scale (YMRS) total score versus placebo at Week 3 (effect size −0.69; p<0.0001), with statistically significant separation observed as early as Day 3. Clinical response, defined as a ≥50% reduction in YMRS total score, was achieved by 45.8% of lumateperone-treated patients versus 20.9% on placebo (p<0.0001). The key secondary endpoint — Clinical Global Impression–Severity (CGI-S) score — also favored lumateperone (least-squares mean difference −0.5; p<0.0001). The most common treatment-related adverse events reported at ≥5% and at least twice the placebo rate were dry mouth (7.9% vs. 3.4%) and nausea (7.9% vs. 2.3%), consistent with lumateperone's established profile across its approved indications.
Lumateperone has a multimodal pharmacology that includes serotonin 5-HT2A receptor antagonism, dopamine D2 receptor modulation, and effects on glutamatergic signaling via GluN2B-containing NMDA receptors. That represents a differentiated pharmacological profile from standard D2 antagonists such as olanzapine and risperidone, and from AbbVie's D3-preferring partial agonist Vraylar (cariprazine). Lumateperone is currently FDA-approved for bipolar I and II depression, schizophrenia, and as adjunctive therapy for major depressive disorder (MDD), but holds no approval for bipolar mania.
Study 451 is the first of two pivotal Phase III studies in this indication. Johnson & Johnson said a second study, Study 452, has been completed and data analysis is underway. The mania program continues alongside established indications: the drug's depression and schizophrenia indications are established, and the FDA approved a supplemental NDA for relapse prevention in schizophrenia in April 2026.